Literature DB >> 29661533

Design, synthesis, and evaluation of novel N-1 fluoroquinolone derivatives: Probing for binding contact with the active site tyrosine of gyrase.

Tyrell R Towle1, Chaitanya A Kulkarni1, Lisa M Oppegard2, Bridget P Williams2, Taylor A Picha2, Hiroshi Hiasa2, Robert J Kerns3.   

Abstract

Structural studies of topoisomerase-fluoroquinolone-DNA ternary complexes revealed a cavity between the quinolone N-1 position and the active site tyrosine. Fluoroquinolone derivatives having positively charged or aromatic moieties extended from the N-1 position were designed to probe for binding contacts with the phosphotyrosine residue in ternary complex. While alkylamine, alkylphthalimide, and alkylphenyl groups introduced at the N-1 position afforded derivatives that maintained modest inhibition of the supercoiling activity of DNA gyrase, none retained ability to poison DNA gyrase. Thus, the addition of a large and/or long moiety at the N-1 position disrupts ternary complex formation, and retained ability to inhibit supercoiling is likely through interference with the strand breakage reaction. Two derivatives were found to possess inhibitory effects on the decatenation activity of human topoisomerase II.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bacterial resistance; DNA gyrase; Fluoroquinolone; Topoisomerase

Mesh:

Substances:

Year:  2018        PMID: 29661533      PMCID: PMC5938125          DOI: 10.1016/j.bmcl.2018.03.085

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  31 in total

Review 1.  DNA topoisomerases: structure, function, and mechanism.

Authors:  J J Champoux
Journal:  Annu Rev Biochem       Date:  2001       Impact factor: 23.643

2.  Type IIA topoisomerase inhibition by a new class of antibacterial agents.

Authors:  Benjamin D Bax; Pan F Chan; Drake S Eggleston; Andrew Fosberry; Daniel R Gentry; Fabrice Gorrec; Ilaria Giordano; Michael M Hann; Alan Hennessy; Martin Hibbs; Jianzhong Huang; Emma Jones; Jo Jones; Kristin Koretke Brown; Ceri J Lewis; Earl W May; Martin R Saunders; Onkar Singh; Claus E Spitzfaden; Carol Shen; Anthony Shillings; Andrew J Theobald; Alexandre Wohlkonig; Neil D Pearson; Michael N Gwynn
Journal:  Nature       Date:  2010-08-04       Impact factor: 49.962

Review 3.  Clinical use of the fluoroquinolones.

Authors:  R C Owens; P G Ambrose
Journal:  Med Clin North Am       Date:  2000-11       Impact factor: 5.456

4.  DNA gyrase-mediated wrapping of the DNA strand is required for the replication fork arrest by the DNA gyrase-quinolone-DNA ternary complex.

Authors:  H Hiasa; M E Shea
Journal:  J Biol Chem       Date:  2000-11-03       Impact factor: 5.157

5.  Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage.

Authors:  Carrie Anna Geisberg; Douglas B Sawyer
Journal:  Curr Hypertens Rep       Date:  2010-12       Impact factor: 5.369

6.  Fluoroquinolone prescribing in the United States: 1995 to 2002.

Authors:  Jeffrey A Linder; Elbert S Huang; Michael A Steinman; Ralph Gonzales; Randall S Stafford
Journal:  Am J Med       Date:  2005-03       Impact factor: 4.965

7.  Structural basis of gate-DNA breakage and resealing by type II topoisomerases.

Authors:  Ivan Laponogov; Xiao-Su Pan; Dennis A Veselkov; Katherine E McAuley; L Mark Fisher; Mark R Sanderson
Journal:  PLoS One       Date:  2010-06-28       Impact factor: 3.240

Review 8.  Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success.

Authors:  Liam S Redgrave; Sam B Sutton; Mark A Webber; Laura J V Piddock
Journal:  Trends Microbiol       Date:  2014-05-16       Impact factor: 17.079

Review 9.  The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing.

Authors:  Joseph E Deweese; Neil Osheroff
Journal:  Nucleic Acids Res       Date:  2008-11-28       Impact factor: 16.971

Review 10.  Ubiquitous Nature of Fluoroquinolones: The Oscillation between Antibacterial and Anticancer Activities.

Authors:  Temilolu Idowu; Frank Schweizer
Journal:  Antibiotics (Basel)       Date:  2017-11-07
View more
  6 in total

1.  Novel N-1 substituted fluoroquinolones inhibit human topoisomerase I activity and exhibit anti-proliferative activity.

Authors:  Lisa M Oppegard; Justine L Delgado; Chaitanya A Kulkarni; Tyrell R Towle; Delaney E Hart; Bridget P Williams; Sarah R C Lentz; Beverly J Norris; Craig M Flory; Robert J Schumacher; Daryl J Murry; Robert J Kerns; Hiroshi Hiasa
Journal:  Invest New Drugs       Date:  2018-09-10       Impact factor: 3.850

2.  Probing structural requirements for human topoisomerase I inhibition by a novel N1-Biphenyl fluoroquinolone.

Authors:  Justine L Delgado; Sarah R C Lentz; Chaitanya A Kulkarni; Pratik R Chheda; Hailey A Held; Hiroshi Hiasa; Robert J Kerns
Journal:  Eur J Med Chem       Date:  2019-03-20       Impact factor: 6.514

3.  Identification of an ethyl 5,6-dihydropyrazolo[1,5-c]quinazoline-1-carboxylate as a catalytic inhibitor of DNA gyrase.

Authors:  Arturo L Aguirre; Pratik R Chheda; Sarah R C Lentz; Hailey A Held; Natalie P Groves; Hiroshi Hiasa; Robert J Kerns
Journal:  Bioorg Med Chem       Date:  2020-03-13       Impact factor: 3.641

Review 4.  DNA Topoisomerase Inhibitors: Trapping a DNA-Cleaving Machine in Motion.

Authors:  Benjamin D Bax; Garib Murshudov; Anthony Maxwell; Thomas Germe
Journal:  J Mol Biol       Date:  2019-07-10       Impact factor: 5.469

5.  Design, Synthesis and Biological Evaluation of New Piperazin-4-yl-(acetyl-thiazolidine-2,4-dione) Norfloxacin Analogues as Antimicrobial Agents.

Authors:  Gabriel Marc; Cătălin Araniciu; Smaranda Dafina Oniga; Laurian Vlase; Adrian Pîrnău; George Cosmin Nadăș; Cristiana Ștefania Novac; Ioana Adriana Matei; Mariana Carmen Chifiriuc; Luminița Măruțescu; Ovidiu Oniga
Journal:  Molecules       Date:  2019-10-31       Impact factor: 4.411

Review 6.  Fluoroquinolones' Biological Activities against Laboratory Microbes and Cancer Cell Lines.

Authors:  Ghadeer A R Y Suaifan; Aya A M Mohammed; Bayan A Alkhawaja
Journal:  Molecules       Date:  2022-03-03       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.